Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,692 shares of the medical research company’s stock after acquiring an additional 718 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Edwards Lifesciences were worth $2,050,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $30,000. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences in the fourth quarter valued at $46,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EW has been the subject of a number of research reports. Royal Bank of Canada boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Piper Sandler lowered their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, The Goldman Sachs Group boosted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $79.19.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,000 shares of company stock valued at $547,430. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Up 1.0 %

NYSE:EW opened at $71.05 on Tuesday. The stock’s fifty day moving average price is $72.45 and its two-hundred day moving average price is $69.18. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $41.91 billion, a price-to-earnings ratio of 10.25, a P/E/G ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.